LR Health & Beauty published its final annual report for 2025. Included in the report were preliminary full-year 2025 sales totals, which reached $319 million, down from $333 million in 2024. EBITDA for 2025 is reported at $19 million, compared to $31 million in 2024. Normalized EBITDA for the year was approximately $25.9 million.

LR Health & Beauty announced a more than $2 million investment in its Ahlen, Germany headquarters as it prepares for future growth. Included in this investment is a new production line that will consolidate the manufacturing of its 5-in-1 products while creating opportunities for future product developments within the nutritional supplement category.

LR Health & Beauty reported its financial results for the first quarter of 2026. Sales in the quarter reached $71.6 million with a normalized EBITDA of $6.12 million. Sales fell 17.8% year-over-year.

LR Health & Beauty announced a new generation of products in the “beauty food” category with the LR 5in1 Beauty Elixir and the LR 5in1 Men’s Shot. These new product formulations are tailored to support the body through daily stressors and environmental influences by providing nutrients in proportions that achieve higher potential efficacy.

LR Health & Beauty announced its financial results for the fourth quarter 2025 and preliminary sales and earnings results for full year 2025. Revenue during the quarter was $80.3 million, a 10.9% decline that the company attributed to subdued consumer sentiment in Western European markets.

LR Health & Beauty SE has reached an agreement with significant investors to realign its financing structure. This comprehensive restructuring of its 2024/2028 Bond and capital structure is expected to provide for an aggregate injection of fresh capital of $23 million and significantly reduce and restructure the company’s debt